Menu
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Fribourg, Switzerland.
rue Louis-d'Affry 6
http://www.alcon.com
Alcon is delivering solid, but hardly spectacular revenue growth, and is seeing much better free cash flow. Here''s why ALC shares should be avoided for now.
The Cooper Companies (COO) stock gains after Jefferies upgrades to Buy, citing unjustified valuation discrepancy with rival Alcon (ALC). Read more here.
Staar Surgical (STAA) stock jumps 4% on takeover speculation by Alcon (ALC), according to a report from StreetInsider.
Investors in Alcon Inc. (NYSE: ALC ) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 16, 2024 $40 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could … Full story available on Benzinga.com
Alcon (ALC) has released an update. Alcon has announced U.S. FDA 510(k) clearance for its innovative Unity VCS and Unity CS surgical systems, marki…
WASHINGTON (dpa-AFX) - Eye care company Alcon Inc. (ALC) announced Monday that UNITY Vitreoretinal Cataract System or VCS and UNITY Cataract System or CS have received U.S. Food and Drug Administr…
Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovatio…
Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY Vitreoretinal Cataract System (VCS) and UNITY Cataract System (CS) have received U.S. Food and Drug Administration (FDA) 510(k) clearance. These innovations are the first to be introduced from Alcon’s highly anticipated Unity portfolio. “At Alcon, Jetzt den vollständigen Artikel lesen
Alcon''s Unity VCS and CS gain FDA clearance, aiming to revolutionize ophthalmic surgery with enhanced efficiencies. Commercial launch expected in 2025.